BMS withdraws its application in the EU for Opdivo + Yervoy combination for the treatment of advanced NSCLC.
Related news and insights
Merck Inc., provided an update on the open-label arm of the non-registrational Phase II KeyVibe-002 trial. KeyVibe-002 is evaluating MK 7684A, a coformulation of vibostolimab, an anti-TIGIT therapy, and pembrolizumab (Keytruda), Merck’s anti-PD-1 therapy, with or without docetaxel for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with progressive disease after treatment with immunotherapy and platinum-doublet chemotherapy
Positive high-level results from a planned interim analysis of the AEGEAN Phase III, placebo- controlled trial showed that treatment with AstraZeneca’s Imfinzi (durvalumab) in combination with neoadjuvant chemotherapy before surgery and as adjuvant monotherapy after surgery demonstrated a statistically significant and clinically meaningful improvement in event-free survival (EFS) versus neoadjuvant chemotherapy alone followed by surgery for patients with resectable early-stage (IIA-IIIB) non-small cell lung cancer (NSCLC)
Merck Inc. announced that the Phase III KEYNOTE-671 trial investigating Keytruda (pembrolizumab), Merck’s anti-PD-1 therapy, met one of its dual primary endpoints, event-free survival (EFS), as a perioperative treatment regimen for patients with resectable stage II, IIIA or IIIB non-small cell lung cancer (NSCLC)